For diffuse astrocytic glioma, the 2021 5th edition of the WHO Classification of Tumors of the Central Nervous System reflects the discovery of molecular markers underlying neoplasms of the central nervous system, such as in isocitrate dehydrogenase 1/2 (IDH1/IDH2), ATP-dependent helicase ATRX (ATRX), histone H3-K27M, and the 1p/19q chromosomal deletion [87]. Here, ATRX is linked to central nervous system neoplasm.